The pharma launch market has settled the question of which tools to use. It still hasn't answered the only question that decides the launch: who is in the room. The short version: The platforms are real and the value is there, but the edge was never in owning the software. The gap nobody sells into is the person who runs it against your molecule, with authority to act. The 2027 launches that look effortless will belong to whoever put control back in the room. Six posts ago I

I have pulled together launch dashboards. Most tell you what happened, and by the time the room agrees on why, the window has moved. Lou Pillai calls the fix the orchestration layer, and is blunt that it is not a program management exercise. The capability worth sitting with: AI can surface the heuristics your 30-year super specialist carries in their head, while the decision is still live. One line stays above the dashboard. AI cannot take accountability. Having launched mul

"AI predicts launch success" is the line everyone is selling right now. It also happens to be pointed at the easier half of the problem. The short version: Predictive launch tracking is real, and the people running pharma's biggest AI programs are still careful about the claim. Prediction works when a problem holds still, and a launch doesn't. The ROI lives in response time, not in the forecast, so buy the sensor and build the reflexes. IQVIA describes active launch tracking

Your best launch plan has a shelf life of about three months. That is how long a single tactic has traditionally taken to turn around, inside a window that runs six months to a year. Lou Pillai on what changes when a launch runs as a closed loop rather than a static map. The stakes show up at patient access, where a two-week wait starts costing you prescribers. That three months is the honest number: rework the content, re-run the review, get it back into the field. Teams can

That gap, between knowing what good looks like and being able to act while the market is still moving, is what I wanted to put to someone who has lived it. Lou has spent three decades in commercialization and has since sat on the other side of the table, advising the teams making these calls. Not a vendor with a platform to sell. An operator who has watched launches drift in real time and can tell you where and why. My thanks to him for a genuinely candid hour, and for being

Every big firm is now selling the same pharma launch. Agentic. Sense-and-respond. "Launch as a learning system." They are all describing the same thing, and none of them is in the room when it fails. The short version: The big-firm launch point of view has converged, and the platforms behind it are real. Launches still drift anyway, because the gap was never structure. It was control. The question isn't which agentic platform to buy. It's who holds the loop closed when the ma